Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.
ICI (immune checkpoint inhibitor)
M-MDSCs (monocytic myeloid-derived suppressor cells), c-FLIP (cellular FLICE [FADD-like IL-1β-converting enzyme]- inhibitory protein)
NSCLC (non-small cell lung cancer)
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
19
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Cancer cells favor the generation of myeloid cells with immunosuppressive and inflammatory features, including myeloid-derived suppressor cells (MDSCs), which support tumor progression. The anti-apoptotic molecule, cellular FLICE (FADD-like interleukin-1β-converting enzyme)-inhibitory protein (c-FLIP), which acts as an important modulator of caspase-8, is required for the development and function of monocytic (M)-MDSCs. Here, we assessed the effect of immune checkpoint inhibitor (ICI) therapy on systemic immunological landscape, including FLIP-expressing MDSCs, in non-small cell lung cancer (NSCLC) patients. Longitudinal changes in peripheral immunological parameters were correlated with patients' outcome. In detail, 34 NSCLC patients were enrolled and classified as
Identifiants
pubmed: 37720688
doi: 10.1080/2162402X.2023.2253644
pii: 2253644
pmc: PMC10503454
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2253644Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Nat Med. 2021 Dec;27(12):2212-2223
pubmed: 34887574
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35022194
Endocrinology. 2013 Sep;154(9):3077-88
pubmed: 23836031
Cancer Res. 2021 Jun 15;81(12):3295-3308
pubmed: 33853830
Thorac Cancer. 2018 Jul;9(7):775-784
pubmed: 29722145
Semin Immunol. 2012 Jun;24(3):218-24
pubmed: 22410365
Sci Transl Med. 2023 Mar 15;15(687):eabq6221
pubmed: 36921034
J Clin Invest. 2020 Dec 1;130(12):6409-6416
pubmed: 32809969
Nat Rev Clin Oncol. 2021 Oct;18(10):625-644
pubmed: 34168333
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Invest. 2015 Sep;125(9):3365-76
pubmed: 26325033
JAMA Oncol. 2018 Mar 01;4(3):351-357
pubmed: 29327044
Cytokine. 2023 Mar;163:156133
pubmed: 36724715
Nat Rev Immunol. 2005 Aug;5(8):641-54
pubmed: 16056256
Cell Death Differ. 2022 Feb;29(2):420-438
pubmed: 34518653
J Exp Med. 2022 Jun 6;219(6):
pubmed: 35604411
Ann Oncol. 2021 Dec;32(12):1597-1607
pubmed: 34487855
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32238470
Signal Transduct Target Ther. 2019 Dec 17;4:61
pubmed: 31871778
J Immunother Cancer. 2019 Sep 18;7(1):255
pubmed: 31533831
Cells. 2021 Oct 09;10(10):
pubmed: 34685679
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
J Clin Invest. 2020 Jul 1;130(7):3865-3884
pubmed: 32324593
J Exp Med. 2011 Sep 26;208(10):1949-62
pubmed: 21930770
J Med Chem. 2020 Mar 26;63(6):3047-3065
pubmed: 32150677
Nat Rev Clin Oncol. 2021 Sep;18(9):547-557
pubmed: 33911215
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
Nat Commun. 2020 Aug 11;11(1):4011
pubmed: 32782249
Nat Methods. 2019 Mar;16(3):243-245
pubmed: 30742040
Nat Rev Clin Oncol. 2020 Feb;17(2):73-74
pubmed: 31907372
PLoS One. 2017 Jul 17;12(7):e0181125
pubmed: 28715437
J Immunother Cancer. 2022 May;10(5):
pubmed: 35618288
J Thorac Oncol. 2021 Jun;16(6):922-932
pubmed: 33581342
Immunity. 2014 Dec 18;41(6):947-59
pubmed: 25500368
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Nat Rev Clin Oncol. 2020 May;17(5):300-312
pubmed: 32055013
Front Immunol. 2020 Jul 24;11:1590
pubmed: 32793228
Ann N Y Acad Sci. 2014 Jun;1319:47-65
pubmed: 24965257
Front Microbiol. 2022 Apr 06;13:874998
pubmed: 35464987
Cancer Immunol Res. 2021 Nov;9(11):1316-1326
pubmed: 34518197
J Immunother Cancer. 2022 Jun;10(6):
pubmed: 35718373
Clin Lung Cancer. 2019 Jul;20(4):e514-e516
pubmed: 31122866
Cancer Cell. 2023 Apr 10;41(4):693-710.e8
pubmed: 36963400
Nat Rev Clin Oncol. 2022 Aug;19(8):499-514
pubmed: 35534623
Cell Res. 2019 Oct;29(10):846-861
pubmed: 31481761
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Annu Rev Med. 2020 Jan 27;71:117-136
pubmed: 31986082
Biochim Biophys Acta. 2016 Jan;1865(1):35-48
pubmed: 26255541
Curr Protoc Immunol. 2019 Feb;124(1):e61
pubmed: 30303619
Br J Cancer. 2019 Jan;120(1):16-25
pubmed: 30413826
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Cancer Res. 2021 Feb 15;81(4):956-967
pubmed: 33293426
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369
pubmed: 30545915
Cancer Discov. 2021 Nov;11(11):2693-2706
pubmed: 34635571
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Front Immunol. 2019 Jun 06;10:925
pubmed: 31244820
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Cytometry A. 2006 Jun;69(6):541-51
pubmed: 16604519
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
Cancer Cell. 2022 May 9;40(5):509-523.e6
pubmed: 35537412
Int J Mol Sci. 2018 Oct 18;19(10):
pubmed: 30340321
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Cancer Cell. 2022 Jun 13;40(6):674-693.e7
pubmed: 35594863
Nat Commun. 2018 Dec 5;9(1):5193
pubmed: 30518925
Blood. 2002 Aug 15;100(4):1215-9
pubmed: 12149200
Front Oncol. 2020 Feb 18;10:165
pubmed: 32133298
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
Blood. 2001 Jan 1;97(1):256-63
pubmed: 11133769
JAMA. 2001 Jul 18;286(3):327-34
pubmed: 11466099